Sökning: onr:"swepub:oai:DiVA.org:uu-304460" > Long-term evaluatio...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05057naa a2200505 4500 | |
001 | oai:DiVA.org:uu-304460 | |
003 | SwePub | |
008 | 161005s2016 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3044602 URI |
024 | 7 | a https://doi.org/10.1093/europace/euv3122 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Ezekowitz, Michael D.u Thomas Jefferson Univ, Sidney Kimmel Med Coll, 1999 Sproul Rd, Philadelphia, PA 19107 USA.;Lankenau Med Ctr, Wynnewood, PA USA.4 aut |
245 | 1 0 | a Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation |
264 | c 2016-03-03 | |
264 | 1 | b Oxford University Press (OUP),c 2016 |
338 | a print2 rdacarrier | |
520 | a Aims The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial allowed patients who completed the trial receiving their assigned dabigatran 150 mg (D150) or 110 mg (D110) twice a day to continue into the Long-term Multicenter Extension of Dabigatran Treatment in Patients with Atrial Fibrillation (RELY-ABLE) trial. This permitted assessment of outcomes over a median of 4.6 and a maximum of 6.7 years, respectively. Methods and results The analysed population included only those patients who completed RE-LY on dabigatran and continued into RELYABLE without interruption of assigned dabigatran. Cumulative risk was expressed as Kaplan-Meier plots. Outcomes were compared using Cox proportional hazard modelling. Stroke or systemic embolization rates were 1.25 and 1.54% per year (D150 and D110, respectively); hazard ratio (HR) 0.81 [95% confidence interval (CI): 0.68-0.96] (P = 0.02). Ischaemic stroke was 1.03 (D150) and 1.29%/year (D110); HR 0.79 (95% CI: 0.66-0.95) (P = 0.01). Haemorrhagic stroke rates were 0.11 (D150) and 0.13%/year (D110); HR 0.91 (95% CI: 0.51-1.62) (P = 0.75). Rates of major haemorrhage were 3.34 (D150) and 2.76%/year (D110); HR 1.22 (95% CI: 1.08-1.37) (P = 0.0008). Intracranial haemorrhage rates were 0.32 (D150) and 0.23%/year (D110); HR 1.37 (95% CI: 0.93-2.01) (P = 0.11). Mortality was 3.43 (D150) and 3.55%/year (D110); HR 0.97 (95% CI: 0.87-1.08) (P = 0.54). Conclusion Annualized rates of all outcomes were constant with better efficacy of D150, less major bleeding with D110, and low intracerebral haemorrhage rates for both doses. There were no additional safety concerns. This is the longest continuous randomized experience of a novel anticoagulant. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng |
653 | a Atrial fibrillation | |
653 | a Stroke | |
653 | a Dabigatran etexilate | |
653 | a Long-term outcome | |
700 | 1 | a Eikelboom, Johnu McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada.;Hamilton Hlth Sci, Hamilton, ON, Canada.4 aut |
700 | 1 | a Oldgren, Jonasu Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi4 aut0 (Swepub:uu)jonaoldg |
700 | 1 | a Reilly, Paul A.u Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA.4 aut |
700 | 1 | a Brueckmann, Martinau Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany.;Heidelberg Univ, Fac Med Mannheim, Mannheim, Germany.4 aut |
700 | 1 | a Kent, Anthony P.u Thomas Jefferson Univ, Sidney Kimmel Med Coll, 1999 Sproul Rd, Philadelphia, PA 19107 USA.4 aut |
700 | 1 | a Pogue, Janiceu McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada.;Hamilton Hlth Sci, Hamilton, ON, Canada.4 aut |
700 | 1 | a Spahr, Judithu Lankenau Inst Med Res, Wynnewood, PA USA.4 aut |
700 | 1 | a Clemens, Andreasu Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany.4 aut |
700 | 1 | a Noack, Herbertu Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany.4 aut |
700 | 1 | a Diener, Hans-Christophu Univ Hosp Essen, Dept Neurol, Essen, Germany.4 aut |
700 | 1 | a Wallentin, Larsu Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi4 aut0 (Swepub:uu)larswall |
700 | 1 | a Yusuf, Salimu McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada.;Hamilton Hlth Sci, Hamilton, ON, Canada.4 aut |
700 | 1 | a Connolly, Stuart J.u McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada.;Hamilton Hlth Sci, Hamilton, ON, Canada.4 aut |
710 | 2 | a Thomas Jefferson Univ, Sidney Kimmel Med Coll, 1999 Sproul Rd, Philadelphia, PA 19107 USA.;Lankenau Med Ctr, Wynnewood, PA USA.b McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada.;Hamilton Hlth Sci, Hamilton, ON, Canada.4 org |
773 | 0 | t Europaced : Oxford University Press (OUP)g 18:7, s. 973-978q 18:7<973-978x 1099-5129x 1532-2092 |
856 | 4 | u https://academic.oup.com/europace/article-pdf/18/7/973/24119643/euv312.pdf |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-304460 |
856 | 4 8 | u https://doi.org/10.1093/europace/euv312 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy